Computational docking can be used to predict bound conformations and free energies of binding for small-molecule ligands to macromolecular targets. Docking is widely used for the study of biomolecular interactions and mechanisms, and it is applied to structure-based drug design. The methods are fast enough to allow virtual screening of ligand libraries containing tens of thousands of compounds. This protocol covers the docking and virtual screening methods provided by the AutoDock suite of programs, including a basic docking of a drug molecule with an anticancer target, a virtual screen of this target with a small ligand library, docking with selective receptor flexibility, active site prediction and docking with explicit hydration. The entire protocol will require ~5 h.
At a glance
- AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J. Comput. Chem. 31, 455–461 (2010). &
- Automated docking of substrates to proteins by simulated annealing. Proteins 8, 195–202 (1990). &
- Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J. Comput. Chem. 19, 1639–1662 (1998). et al.
- Forli, S. Raccoon for Processing Virtual Screening <http://autodock.scripps.edu/resources/raccoon> (2013).
- AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility. J. Comput. Chem. 30, 2785–2791 (2009). et al.
- Automated prediction of ligand-binding sites in proteins. Proteins 70, 1506–1517 (2008). , &
- Protein-ligand docking in the new millennium—a retrospective of 10 years in the field. Curr. Med. Chem. 20, 2296–2314 (2013). et al.
- Automated docking in crystallography: analysis of the substrates of aconitase. Proteins 17, 1–10 (1993). , , &
- Automated docking of flexible ligands: applications of AutoDock. J. Mol. Recognit. 9, 1–5 (1996). , &
- Docking of 4-oxalocrotonate tautomerase substrates: implications for the catalytic mechanism. Biolpolymers 50, 319–328 (1999). , , , &
- Automated docking of ligands to an artificial active site: augmenting crystallographic analysis with computer modeling. J. Comput. Aided Mol. Des. 17, 525–536 (2003). et al.
- Rapid diversity-oriented synthesis in microtiter plates for in situ screening of HIV protease inhibitors. ChemBioChem 4, 1246–1248 (2003). et al.
- 1,2,3-Triazole as a peptide surrogate in the rapid synthesis of HIV-1 protease inhibitors. ChemBioChem 6, 1167–1169 (2005). et al.
- Fragment-based screen against HIV protease. Chem. Biol. Drug Des. 75, 257–268 (2010). et al.
- Structure-based virtual screening and biological evaluation of Mycobacterium tuberculosis adenosine 5′-phosphosulfate reductase inhibitors. J. Med. Chem. 51, 6627–6630 (2008). et al.
- A virtual screen discovers novel, fragment-sized inhibitors of Mycobacterium tuberculosis InhA. J. Chem. Inf. Model. 55, 645–659 (2015). et al.
- Identification of novel beta-secretase inhibitors through inclusion of protein flexibility in virtual screening calculations. FASEB J. 22, 791–798 (2008). et al.
- Protein flexibility in virtual screening: the BACE-1 case study. J. Chem. Inf. Model. 52, 2697–2704 (2012). et al.
- Stabilizers of the Max homodimer identified in virtual ligand screening inhibit Myc function. Mol. Pharmacol. 76, 491–502 (2009). et al.
- Redox-based probes for protein tyrosine phosphatases. Angew. Chem. Int. Ed. Engl. 50, 4423–4427 (2011). , , &
- Grid-based hydrogen bond potentials in improved directionality. Lett. Drug Des. Discov. 1, 178–183 (2004). , , &
- A semiempirical free energy force field with charge-based desolvation. J. Comput. Chem. 28, 1145–1152 (2006). , , &
- A force field with discrete displaceable waters and desolvation entropy for hydrated ligand docking. J. Med. Chem. 55, 623–638 (2012). &
- Covalent docking using autodock: two-point attractor and flexible side chain methods. Protein Sci. 25, 295–301 (2016). , , &
- Virtual screening with AutoDock: theory and practice. Expert Opin. Drug Discov. 5, 597–607 (2010). et al.
- The relaxed complex method: accommodating receptor flexibility for drug design with an improved scoring scheme. Biopolymers 68, 47–62 (2003). , , &
- Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res. 62, 4236–4243 (2002). et al.
- Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 289, 1938–1942 (2000). et al.